Abstract 205P
Background
The real-life experience of radium-223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC) in Asia is limited. In recent ERA223 study, the post-treatment osteoporotic fracture risk was unexpectedly found elevated when Ra223 was given in addition to abiraterone/prednisone in mCRPC, raising a concern of long-term bone safety with Ra223.
Methods
Hospital records of consecutive patients with mCRPC treated with Ra223 in 5 Hong Kong public hospitals from Nov 2015 to Oct 2018 were retrieved for the analysis of treatment pattern and clinical outcomes.
Results
We identified 42 men with bony mCRPC (median age: 73; 78.6% ECOG PS 0/1; 61.9% with bone pain; 50% lymphadenopathy; 14.3% visceral metastases) who received at least 1 dose of Ra233 (median 6, IRQ: 4-6). Median follow-up was 8.8 months. Ra223 was administered at a median of 3rd line setting (IQR: 2nd to 4th line) with 88.1% and 35.7% having prior androgen-receptor axis-targeted agents (ARTAs, i.e. abiraterone and enzalutamide) and docetaxel. Ra223 was used concomitantly with ARTAs and bone health agents at 23.8% and 45.2%, respectively. 64.5% of patients had subsequent therapies (16.7% chemotherapy; 42.9% ARTAs). Median time to PSA progression was 3.6 months (IQR: 3.5-4.5) and 48.6% (18/37) had 30% drop of ALP after 3rd injection. 26.9% (7/26) with bone pain requiring analgesics had symptomatic improvement but 15% had worsened pain. 66.7% of patients were free from symptomatic skeletal event (SSE), with 6-month and 1-year SSE rates being 11.9% and 26.2%. The median OS was 18.2 months (95%CI: 4.6-31.9) and was longer for patients who received >4 injections (27.7 vs 7.8 months, p = 0.015). The most common AEs were anemia (67%), fatigue (36%), bone pain (33%), thrombocytopenia (26%) and neutropenia (19%). Treatment discontinuation due to AEs was 8%. Non-osteoporotic fracture was seen in 3 patients (2 pathological and 1 traumatic).
Conclusions
Later line use of Ra223 was a common real-life practice. Efficacy and tolerability with Ra223 remains favorable in heavily-pretreated mCRPC, despite higher rate of hematological AE was seen. With nearly ¼ patients with concomitant ARTAs, osteoporotic fracture was not seen in this cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract